National Multiple Sclerosis Society

The excellent technical assistance of Everett Swanson, Howard Finch and Miriam Pakingan is appreciated. The work represented by this chapter was supported in part by USPHS Grants NS 08952 and NS 11920 and by Grant NMSS RG 1001-J-10 from the National Multiple Sclerosis Society. The author is the Wollowick Family Foundation Professor in Multiple Sclerosis Research at this institution. 

United States Public Health Service, the National Science Foundation, the Office of Naval Research, the Mental Health Association, the National Multiple Sclerosis Society, the Williams-Waterman Fund of Research Foundation Inc., and the National Vitamin Foundation. 

Opinions vary on when to initiate treatment with interferon-p. According to the National Multiple Sclerosis Society, these agents should be considered in patients with relapsing-remitting MS who have had recent relapses. Some neurologists delay treatment until there is a more prolonged history of recurrent relapses, because, in their experience, patients may have a benign early course. 

AcknoMdedgements. This study was supported by grants from National Institutes of Health (NS39940 and NS48923), National Multiple Sclerosis Society (RG3422A1/1) and Michael J. Fox Foundation for Parkinson Research. 

Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 46 907-911. 

The National Multiple Sclerosis Society in the USA made a statement referring to anecdotal reports suggesting that immunization against hepatitis B may increase the risk of multiple sclerosis (27). They noted that ... 

Medical Advisory Board of the National Multiple Sclerosis Society Statement from 14 August 1998. National Multiple... 

Research described in this chapter has been supported, in part, by grants from the National Multiple Sclerosis Society, and from the Rehabilitation Research Service and Medical Research Service, Department of Veterans Affairs. We also thank the Eastern Paralysed Veterans Association and the Paralysed Veterans of America for support, including a gift that supports the Yale—London Collaboration. 

Despite encouraging results from well-conducted clinical trials, several relevant issues remain. The most important question in the use of the ABC-R drugs is when to begin therapy. The Medical Advisory Board of the National Multiple Sclerosis Society has adopted recommendations regarding the use of the current MS disease-modifying agents, and these are summarized in Table 53-3. ... 

National Multiple Scleosis Society (2005) Two new oral drugs show positive results in preliminary trials in multiple sclerosis. NMSS Res Clin Updates. June 2, 2005 1—2. 

The author would like to acknowledge his former colleagues David Edgar and Rupert Timpl for their support during his initiation into the laminin field. He is supported by the National Health and Medical Research Council of Australia, the Australian Research Council, the Multiple Sclerosis Society of Australia and the A.L.S.-Motor Neurone Disease Society of Australia. 

Grant support for published and unpublished work was obtained from the National Institute of Health, Multiple Sclerosis Society, and Milheim Foundation. 

---